Demographic data and peripheral B cells in patients and healthy donors, respectively
Donor | Diagnosis | Sexa | Age (years) | WBC (Gpt/l) | Frequency of CD19+ Cells (%) | Total No. of CD19+ Cells (1 × 106 cells/l) |
---|---|---|---|---|---|---|
1 | Active SLE | f | 40 | 5.51 | 3.8 | 209 |
5 | Active SLE | f | 43 | 3.6 | 6.9 | 248.8 |
6 | Active SLE | f | 36 | 10.9 | 4.4 | 480 |
10 | Active SLE | f | 31 | 5.6 | 9.7 | 543.2 |
11 | Active SLE | f | 22 | 9.1 | 0.7 | 63.7 |
13 | Active SLE | f | 40 | 4.05 | 2.6 | 105.3 |
2 | SLE | f | 61 | 4.25 | 1.5 | 64 |
3 | SLE | f | 56 | 9.3 | 2.6 | 241.8 |
4 | SLE | f | 33 | 9.61 | 2.8 | 269.1 |
7 | SLE | m | 41 | 6.2 | 0.8 | 50.0 |
8 | SLE | f | 32 | 12.4 | 2.1 | 260.4 |
9 | SLE | m | 22 | 7.0 | 2.8 | 196.0 |
12 | SLE | f | 53 | 4.81 | 3.4 | 163.5 |
14 | Sjögren’s syndrome | f | 72 | 7.2 | 2.0 | 144.0 |
15 | Sjögren’s syndrome | f | 17 | 5.3 | 6.3 | 334 |
16 | Myositis | m | 49 | 9.6 | 2.4 | 230.4 |
17 | Myositis | m | 55 | 7.32 | 5.1 | 373.3 |
18 | Scleroderma | f | 59 | 10.1 | 33.3 | 3363.3 |
19 | Scleroderma | m | 55 | 8.51 | 6.2 | 527.6 |
20 | Polymyalgia rheumatic | f | 59 | 7.63 | 3.4 | 259.4 |
21 | Polychondritis | f | 26 | 5.64 | 11.3 | 637.3 |
22 | Inhibitory hemophilia A | f | 64 | 6.4 | 5.9 | 377.6 |
23 | Healthy control | f | 57 | 6.2 | 9.5 | 589 |
24 | Healthy control | f | 31 | 4.5 | 6.9 | 310.5 |
25 | Healthy control | f | 63 | 9.8 | 8.2 | 803.6 |
26 | Healthy control | m | 34 | 5.6 | 8.5 | 476 |
27 | Healthy control | m | 19 | 10.2 | 7.4 | 754.8 |
28 | Healthy control | m | 64 | 7.3 | 8.4 | 613.2 |
29 | Healthy control | m | 24 | 5.9 | 9.7 | 572.3 |
30 | Healthy control | m | 21 | 5.2 | 10.6 | 551.2 |
31 | Healthy control | m | 19 | 6.3 | 7.2 | 453.6 |
32 | Healthy control | f | 39 | 4.9 | 10.5 | 514.5 |
33 | Healthy control | m | 37 | 8.4 | 7.0 | 588 |
34 | Healthy control | m | 38 | 6.2 | 6.2 | 384.4 |
35 | Healthy control | f | 35 | 12.3 | 9.9 | 1217.7 |
36 | Healthy control | m | 37 | 6.82 | 15.1 | 1029.8 |
a f, Female; m, male.